secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigilon Therapeutics, Inc. (—)
CIK:        0001821323
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001193125-23-210739
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sigilon Therapeutics acquired by Eli Lilly for $14.92/share plus CVR; stock to be delisted
--------------------------------------------------------------------------------

- Tender offer closed with 68.23% of shares tendered; together with parent shares, 76.61% of outstanding shares.
- Each share received $14.92 cash plus one contingent value right (CVR) with potential payments up to $111.64.
- All directors and executive officers resigned; replaced by Eli Lilly designees.
- Nasdaq delisting requested; company intends to file Form 15 to suspend SEC reporting.
- Merger completed under DGCL Section 251(h) without stockholder vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/0001193125-23-210739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821323/000119312523210739/d510415d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-210739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer